EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing

Contributed by: PR Newswire

Tags

EQT-Vaderis-152-Mil

More Like This

PR Newswire associated0

Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

EQT Life Sciences participates in RQ Bio's USD 115 million Series A financing

EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio

EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

PR Newswire associated0

Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

EQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases